The investigations target specific transaction terms for four separate entities. Forte Biosciences shareholders are slated to receive $77.00 per share in cash following its sale to argenx BV, while Luxfer Holdings investors are positioned to receive $17.37 per share under an agreement with affiliates of Wynnchurch Capital L.P.
Monteverde & Associates Launches Merger Investigations
Four publicly traded companies face new scrutiny from New York-based Monteverde & Associates PC as the firm investigates recent acquisition deals. Attorney Juan Monteverde is currently reviewing the terms of proposed sales involving Forte Biosciences, Luxfer Holdings, Sanara MedTech, and MarketAxess to ensure shareholder interests are protected during these transitions.
Sanara MedTech faces a more complex arrangement, with shareholders set to receive $33.00 in cash alongside 0.4735 shares of MiMedx common stock per share held. Meanwhile, the investigation into MarketAxess Holdings concerns its acquisition by Intercontinental Exchange, Inc., where shareholders expect a cash payout of $167.00 per share. The firm, which maintains offices in the Empire State Building, is encouraging investors to contact them for further evaluation of these deals.
Comments (0)
No comments yet. Be the first!